CYTOPROTECTIVE PHARMACEUTICAL COMBINATION WHICH CAN BE USED IN THE PREVENTION AND TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME

The invention relates to a pharmacological combination of a protein with cytoprotective properties and an immunomodulatory peptide. The peptide of the pharmacological combination is the linear LALF31-52 peptide which increases immunological defence mechanisms without inducing an exacerbated inflammatory response. The protein of the pharmacological combination is the epidermal growth factor which has a cytoprotective effect and which activates the signal transduction of cell survival genes. The inventive pharmacological combination confers resistance on the systemic immunocompetent cells in order to withstand damage caused by inflammatory cytokines and by bacterial endotoxins without activating molecular apoptosis pathways. In addition, the pharmacological combination alleviates the inflammatory events of the first stage of sepsis and of the inflammatory response against sterile traumatisms, thereby defending the organism against the invasion of pathogens or against inflammation mediators, without the inflammatory response being deleterious to the integrity thereof.